Sirt2-PROTAC-1
CAS No. 2098487-75-1
Sirt2-PROTAC-1 ( Sirt2-PROTAC-1; Sirt2 PROTAC-1; Sirt2-PROTAC1 )
Catalog No. M13316 CAS No. 2098487-75-1
A novel SirReal-based PROTAC that induces isotype-selective Sirt2 degradation (IC50=0.25 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSirt2-PROTAC-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel SirReal-based PROTAC that induces isotype-selective Sirt2 degradation (IC50=0.25 uM).
-
DescriptionA novel SirReal-based PROTAC that induces isotype-selective Sirt2 degradation (IC50=0.25 uM).
-
SynonymsSirt2-PROTAC-1; Sirt2 PROTAC-1; Sirt2-PROTAC1
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPROTAC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2098487-75-1
-
Formula Weight852.94
-
Molecular FormulaC40H40N10O8S2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL 117.24 mM; H2O : < 0.1 mg/mL
-
SMILESO=C(NC1=NC=C(CC2=CC=CC(OCC3=CN(CCCCNC(COC4=CC=CC(C(N5C(CC6)C(NC6=O)=O)=O)=C4C5=O)=O)N=N3)=C2)S1)CSC7=NC(C)=CC(C)=N7
-
Chemical Name2-((4,6-dimethylpyrimidin-2-yl)thio)-N-(5-(3-((1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methoxy)benzyl)thiazol-2-yl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schiedel M, et al. J Med Chem. 2017 Apr 17. doi: 10.1021/acs.jmedchem.6b01872.
molnova catalog
related products
-
Foretinib-Based PROT...
Foretinib-Based PROTAC 7 is a VHL-recruiting PROTAC that induces the degradation of c-Met in a dose- and time-dependent fashion in MDA-MB-231 cells.
-
Lenalidomide-OH
Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.
-
TL13-12
TL13-12 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of TAE684 and the cereblon ligand pomalidomide.